[ Price : $8.95]
The Federal Trade Commission says it appears that two Rx-360 supplier audit programs have a useful purpose and will not harm compe...[ Price : $8.95]
A New England Journal of Medicine editorial faults GlaxoSmithKline for refusing to provide drugs and placebos for government-spons...[ Price : $8.95]
FDA says five companies are recalling products containing aromatase inhibitors they marketed as dietary supplements.[ Price : $8.95]
Federal Register Notice: FDAs Risk Communication Advisory Committee will meet 11/8-9 to discuss ongoing communications programs an...[ Price : $8.95]
FDA's Cardiovascular and Renal Drugs Advisory Committee votes unanimously to recommend approval of Boehringer Ingelheim's blood th...[ Price : $8.95]
Sen. Al Franken calls on FDA to take seriously concerns expressed by Minnesota medical device companies over plans to reform the 5...[ Price : $8.95]
FDA clears an Optovue 510(k) for its Normative Database for the RTVue OCT device used as a reference tool in assessing retina nerv...[ Price : $8.95]
A New York Times article describes the debate over whether new genetically engineered cancer treatments are best evaluated through...